research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
Search
for
Sort by
Research
120-150 / 1000+ results research Use of the drug Wolvit® (biotin 5 mg) in treatment of defuse telogenous alopecia
Wolvit® (biotin 5 mg) is effective and safe for treating hair loss and scalp conditions in women.
research Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
Baricitinib helps treat severe hair loss in people over 65.
research Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells
Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
research Intermittent Low-dose Ritlecitinib in Refractory Paediatric Alopecia Areata: A Case Report with Therapeutic Implications
Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
research Alopecia Areata: Hair and Nail Findings in a Patient Undergoing Talquetamab Therapy for Multiple Myeloma
Talquetamab may cause hair loss and skin issues.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.
research Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis
Rituximab can cause skin issues, but baricitinib may help improve them.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Inhibition of Insulin-Like Growth Factor-1–Induced Sebum Production by Bilobetin in Cultured Human Sebocytes
Bilobetin may help reduce acne by decreasing sebum production.
research Balint’s syndrome—missed or mistaken?
The document concludes that early diagnosis of Balint's syndrome is crucial for effective treatment and that understanding drug interactions, like between ritonavir and statins, is important for patient care.
research 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
The document's conclusion cannot be provided because the content is not available.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research 75214 A Picture-Based SALT (vSALT) for Alopecia Areata with Improved Reliability, Non-Scalp Hair Assessment, Pattern Identification, and Adjustment for Androgenetic Alopecia
research Vitiliginous lesions during contact immunotherapy for alopecia in a patient with autoimmune thyroiditis
Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.
research Impact of Previous Alopecia Areata Treatment on Efficacy Responses After 24 and 48 Weeks of Treatment With Ritlecitinib
research Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report
Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
research Dermal Blimp1 Acts Downstream of Epidermal TGFβ and Wnt/β-Catenin to Regulate Hair Follicle Formation and Growth
Blimp1 is crucial for hair follicle growth and skin health.
research 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
Ritlecitinib may help treat alopecia areata by protecting hair follicles.
research Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
research Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
research Bexarotene gel: A new topical therapy for alopecia areata
Bexarotene gel shows promise as a new treatment for alopecia areata.
research Active Antialopecia Chemical Identification of Merremia peltata Leaves and Computational Study toward Androgen Receptor Using Molecular Docking and Molecular Dynamic Simulation
Merremia peltata leaf extract, particularly the bufotalinin compound, shows potential for treating hair loss.
research Folliculitis decalvans associated with erlotinib
Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.